Nagpur
+919405117673
+919405117673

Pazopanib 400 mg Tablets Exporter from India | Global Supply by Cordium Pharmaceuticals Pvt Ltd |

Pazopanib 400 mg Tablets – Trusted Global Oncology Medicine Exporter Cordium Pharmaceuticals Pvt Ltd is a leading global exporter from India specializing in high-quality oncology medicines including Pazopanib 400 mg Tablets, supplied with strict quality compliance and reliable international logistics. We ensure fast and secure delivery worldwide to: United States, Germany, United Kingdom, Netherlands, South Africa, United Arab Emirates, and Brazil. What is Pazopanib 400 mg Used For? Pazopanib 400 mg Tablets are a prescription anti-cancer medication used in targeted therapy. It belongs to the class of tyrosine kinase inhibitors (TKIs) and is commonly prescribed for: Advanced renal cell carcinoma (kidney cancer) Soft tissue sarcoma treatment Inhibiting tumor growth and reducing blood supply to cancer cells Recommended Dosage The usual adult dose is 400 mg to 800 mg once daily, as prescribed by an oncologist Should be taken on an empty stomach (at least 1 hour before or 2 hours after food) Dosage may vary depending on patient condition and medical supervision ⚠️ Strictly use under medical prescription only. Possible Side Effects Some patients may experience side effects such as: High blood pressure Fatigue and weakness Diarrhea or stomach discomfort Loss of appetite Liver function changes Hair color changes Nausea or vomiting Consult a healthcare professional immediately if severe reactions occur. Global Export & Supply by Cordium Pharmaceuticals Pvt Ltd We are committed to high-quality pharmaceutical exports from India with: GMP-certified manufacturing partners Secure packaging and cold-chain logistics (if required) Fast international shipping Regulatory-compliant documentation 📦 Fast Delivery Available to: USA | Germany | UK | Netherlands | South Africa | UAE | Brazil Contact Us for Bulk Orders & Export Inquiries 📞 WhatsApp: +91-9405117673 📧 Email: info@cordiumpharma.com
 2026-04-18T06:50:26

Keywords